Dyadic International, Inc.

Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological foundation drives their research, development, and commercial endeavors, focusing on the creation and manufacturing of various human and animal vaccines and pharmaceutical products. These offerings span a wide range of biological therapeutics, including virus-like particles (VLPs), antigens, monoclonal, bi-specific, and tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, biosimilars, biobetters, and diverse therapeutic enzymes and proteins. A key pipeline asset is DYAI-100, a SARS-CoV-2-RBD antigen vaccine candidate. This candidate is currently slated for a first-in-human Phase 1 clinical trial, with the objective of establishing proof of concept for the development of next-generation, multivariant COVID-19 vaccine candidates. Dyadic also maintains several strategic alliances, including a research and development agreement with VTT Technical Research Centre of Finland, Ltd., a strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., and a collaboration with Syngene International Limited. Established in 1979, the company is headquartered in Jupiter, Florida.

行业

Biotechnology

部门

Healthcare

总部

US

首席执行官

Mark A. Emalfarb

上市以来

2008年1月16日

雇员

5